Man Group’s Verrica Pharmaceuticals VRCA Stock Holding History

Man Group’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,287	Closed	-$93.8K	–	2597
2025 Q4	$93.8K	Buy	+11,287	New	+$62.5K	﹤0.01%	2200
2023 Q1	–	Hold	0	–	–	–	1951

Other funds holding VRCA

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Man Group's VRCA Position: Q1 2026 in Review

Man Group sold out of Verrica Pharmaceuticals (VRCA) in Q1 2026, closing a stake of 11,287 shares — an estimated $93.8K sold.

Man Group first reported a position in VRCA in Q4 2025 and held it in 1 quarter. The position peaked at $93.8K in Q4 2025. 39 funds tracked by Wall St. Rank hold VRCA as of Q1 2026.

Man Group reported no remaining Verrica Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Man Group sold 11,287 Verrica Pharmaceuticals shares in Q1 2026, an estimated $93.8K.
Man Group first reported a position in Verrica Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Man Group's Verrica Pharmaceuticals position peaked at $93.8K in Q4 2025.
39 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.